Velaglucerase alfa
| Clinical data | |
|---|---|
| Routes of administration | Infusion |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Biological half-life | Plasma: 5–12 minutes (absorbed by macrophages) |
| Identifiers | |
| ATC code | A16AB10 |
| ChemSpider | none |
| UNII |
23HYE36B0I  |
| ChEMBL |
CHEMBL1201865 |
| Chemical data | |
| Formula | C2532H3850N672O711S16 |
| Molar mass | 55.5 kg/mol (unglycosylated) |
 (what is this?) (verify) | |
Velaglucerase alfa (trade name VPRIV), manufactured by Shire plc is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme.[1] It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.[2]
Competitive products
Imiglucerase is Genzyme's version of recombinant glucocerebrosidase. It is marketed globally under the trade name of Cerezyme.
In addition, Protalix and Pfizer are working to bring taliglucerase alpha to market in the U.S. The FDA is due to rule on its approvability in February 2011. The companies are expected also to file for marketing authorization in Europe and around the world.
References
- ↑ University of Birmingham: Velaglucerase alfa for type 1 Gaucher’s disease
- ↑ Medical News Today: Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease, 27 February 2010
| ||||||||||||||